{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:37:46Z","timestamp":1787319466322,"version":"build-2736575974"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["749523\/857743"],"award-info":[{"award-number":["749523\/857743"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DGAPA-PAPIIT"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dopamine is an important neurotransmitter that plays a key role in a wide range of both locomotive and cognitive functions in humans. Disturbances on the dopaminergic system cause, among others, psychosis, Parkinson\u2019s disease and Huntington\u2019s disease. Antipsychotics are drugs that interact primarily with the dopamine receptors and are thus important for the control of psychosis and related disorders. These drugs function as agonists or antagonists and are classified as such in the literature. However, there is still much to learn about the underlying mechanism of action of these drugs. The goal of this investigation is to analyze the intrinsic chemical reactivity, more specifically, the electron donor\u2013acceptor capacity of 217 molecules used as dopaminergic substances, particularly focusing on drugs used to treat psychosis. We analyzed 86 molecules categorized as agonists and 131 molecules classified as antagonists, applying Density Functional Theory calculations. Results show that most of the agonists are electron donors, as is dopamine, whereas most of the antagonists are electron acceptors. Therefore, a new characterization based on the electron transfer capacity is proposed in this study. This new classification can guide the clinical decision-making process based on the physiopathological knowledge of the dopaminergic diseases.<\/jats:p>","DOI":"10.1038\/s41598-020-78446-4","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T06:52:15Z","timestamp":1607496735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["New information of dopaminergic agents based on quantum chemistry calculations"],"prefix":"10.1038","volume":"10","author":[{"given":"Guillermo","family":"Goode-Romero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Winnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilich A.","family":"Ibarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubicelia","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Winnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"key":"78446_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/archpsyc.64.1.19","volume":"64","author":"J Perala","year":"2007","unstructured":"Perala, J. et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch. Gen. Psychiatry 64, 19\u201328 (2007).","journal-title":"Arch. Gen. Psychiatry"},{"key":"78446_CR2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders: Diagnostic and Statistical Manual of Mental Disorders","author":"D American-Psychiatric-Association","year":"2013","unstructured":"American-Psychiatric-Association, D. Diagnostic and Statistical Manual of Mental Disorders: Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric Association, Philadelphia, 2013)."},{"key":"78446_CR3","volume-title":"Lewis In Rosenberg\u2019s Molecular and Genetic Basis of Neurological and Psychiatric Disease","author":"DWDA Volk","year":"2015","unstructured":"Volk, D. W. D. A. Lewis In Rosenberg\u2019s Molecular and Genetic Basis of Neurological and Psychiatric Disease (Academic Press, Cambridge, 2015)."},{"key":"78446_CR4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/B978-0-12-398270-4.00039-2","volume-title":"Neurobiology of Brain Disorders","author":"GT Konopaske","year":"2015","unstructured":"Konopaske, G. T. & Coyle, J. T. Schizophrenia. In Neurobiology of Brain Disorders (eds Zigmond, M. J. et al.) 639\u2013654 (Academic Press, Cambridge, 2015)."},{"key":"78446_CR5","volume-title":"Network Neuroscience","author":"F Fr\u00f6hlich","year":"2016","unstructured":"Fr\u00f6hlich, F. Network Neuroscience (Academic Press, Cambridge, 2016)."},{"key":"78446_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/B978-0-08-097086-8.27062-1","volume-title":"International Encyclopedia of Social & Behavioral Sciences","author":"J Zielasek","year":"2015","unstructured":"Zielasek, J. & Gaebel, W. Schizophrenia. In International Encyclopedia of Social & Behavioral Sciences (ed. Wright, J. D.) 9\u201315 (Elsevier, Amsterdam, 2015)."},{"key":"78446_CR7","first-page":"631","volume":"36","author":"L Hosak","year":"2015","unstructured":"Hosak, L. & Hosakova, J. The complex etiology of schizophrenia\u2014general state of the art. Neuroendrocinol. Lett. 36, 631\u2013637 (2015).","journal-title":"Neuroendrocinol. Lett."},{"key":"78446_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jtbi.2009.03.024","volume":"259","author":"A R\u0103dulescu","year":"2009","unstructured":"R\u0103dulescu, A. A multi-etiology model of systemic degeneration in schizophrenia. J. Theor. Biol. 259, 269\u2013279 (2009).","journal-title":"J. Theor. Biol."},{"key":"78446_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1146\/annurev.psych.55.090902.141950","volume":"55","author":"E Walter","year":"2004","unstructured":"Walter, E., Kestler, L., Bollini, A. & Hochman, K. M. SCHIZOPHRENIA: etiology and course. Annu. Rev. Psychol. 55, 401\u2013430 (2004).","journal-title":"Annu. Rev. Psychol."},{"key":"78446_CR10","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.2174\/156802612805289935","volume":"12","author":"B Dean","year":"2012","unstructured":"Dean, B. Neurochemistry of schizophrenia: the contribution of neuroimaging postmortem pathology and neurochemistry in Schizophrenia. Curr. Top. Med. Chem. 12, 2375\u20132392 (2012).","journal-title":"Curr. Top. Med. Chem."},{"key":"78446_CR11","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.2174\/1568026616666160608084834","volume":"16","author":"P Li","year":"2016","unstructured":"Li, P., Snyder, G. L. & Vanover, K. E. Dopamine targeting drugs for the treatment of schizophrenia: past, present and future. Curr. Top. Med. Chem. 16, 3385\u20133403 (2016).","journal-title":"Curr. Top. Med. Chem."},{"key":"78446_CR12","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1126\/science.281.5381.1264","volume":"281","author":"I Wickelgren","year":"1998","unstructured":"Wickelgren, I. A new route to treating schizophrenia?. Science (80-) 281, 1264\u20131265 (1998).","journal-title":"Science (80-)"},{"key":"78446_CR13","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1021\/jm701094q","volume":"51","author":"MJ Marino","year":"2008","unstructured":"Marino, M. J., Knutsen, L. J. & Williams, M. Emerging opportunities for antipsychotic drug discovery in the postgenomic era. J. Med. Chem. 51, 1077\u20131107 (2008).","journal-title":"J. Med. Chem."},{"key":"78446_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.bcp.2017.05.009","volume":"143","author":"C Forray","year":"2017","unstructured":"Forray, C. & Buller, R. Challenges and opportunities for the development of new antipsychotic drugs. Biochem. Pharmacol. 143, 10\u201324 (2017).","journal-title":"Biochem. Pharmacol."},{"key":"78446_CR15","first-page":"267","volume":"110","author":"J Delay","year":"1952","unstructured":"Delay, J., Deniker, P. & Harl, J. M. Therapeutic method derived from hiberno-therapy in excitation and agitation states. Ann. Med. Psychol. (Paris) 110, 267\u2013273 (1952).","journal-title":"Ann. Med. Psychol. (Paris)"},{"key":"78446_CR16","first-page":"184","volume":"4","author":"A Chauhan","year":"2013","unstructured":"Chauhan, A., Mittal, A. & Arora, P. K. Atypical antipsychotics from scratch to the present. Int. J. Pharm. Sci. 4, 184\u2013204 (2013).","journal-title":"Int. J. Pharm. Sci."},{"key":"78446_CR17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","volume":"60","author":"SG Potkin","year":"2003","unstructured":"Potkin, S. G. et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 60, 681\u2013690 (2003).","journal-title":"Arch. Gen. Psychiatry"},{"key":"78446_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1124\/jpet.102.033175","volume":"302","author":"KD Burris","year":"2002","unstructured":"Burris, K. D. et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302, 381\u2013389 (2002).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"78446_CR19","first-page":"1163","volume":"13","author":"MC Mauri","year":"2014","unstructured":"Mauri, M. C. et al. Clinical pharmacology of atypical antipsychotics: an update.  Exp. Clin. Sci. Int. Online J. Adv. Sci. 13, 1163\u20131191 (2014).","journal-title":"Exp. Clin. Sci. Int. Online J. Adv. Sci."},{"key":"78446_CR20","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","volume":"158","author":"S Kapur","year":"2001","unstructured":"Kapur, S. & Seeman, P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis.  Am. J. Psychiatry 158, 360\u2013369 (2001).","journal-title":"Am. J. Psychiatry"},{"key":"78446_CR21","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","volume":"321","author":"J Geddes","year":"2000","unstructured":"Geddes, J., Freemantle, N., Harrison, P. & Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br. Med. J. 321, 1371\u20131376 (2000).","journal-title":"Br. Med. J."},{"key":"78446_CR22","first-page":"385","volume":"26","author":"J Ananth","year":"2001","unstructured":"Ananth, J., Burgoyne, K. S., Gadasalli, R. & Aquino, S. How do the atypical antipsychotics work?. J. Psychiatry Neurosci. 26, 385\u2013394 (2001).","journal-title":"J. Psychiatry Neurosci."},{"key":"78446_CR23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","volume":"47","author":"P Seeman","year":"2002","unstructured":"Seeman, P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 47, 27\u201338 (2002).","journal-title":"Can. J. Psychiatry"},{"key":"78446_CR24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","volume":"20","author":"J Horacek","year":"2006","unstructured":"Horacek, J. et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20, 389\u2013409 (2006).","journal-title":"CNS Drugs"},{"key":"78446_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.mp.4001556","volume":"10","author":"S Miyamoto","year":"2005","unstructured":"Miyamoto, S., Duncan, G. E., Marx, C. E. & Lieberman, J. A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10, 79\u2013104 (2005).","journal-title":"Mol. Psychiatry"},{"key":"78446_CR26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1017\/S1092852917000608","volume":"22","author":"SM Stahl","year":"2017","unstructured":"Stahl, S. M. Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes. CNS Spectr. 22, 375\u2013384 (2017).","journal-title":"CNS Spectr."},{"key":"78446_CR27","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3390\/molecules23082087","volume":"23","author":"P Stepnicki","year":"2018","unstructured":"Stepnicki, P., Kondej, M. & Kaczor, A. Current concepts and treatments of schizophrenia. Molecules 23, 2087 (2018).","journal-title":"Molecules"},{"key":"78446_CR28","first-page":"206","volume":"60","author":"H Laborit","year":"1952","unstructured":"Laborit, H., Huguenard, P. & Aullaume, R. Un nouveau stabilisateur v\u00e9g\u00e9tatif (le 4560 R.P.). Le Press M\u00e9dicale 60, 206\u2013208 (1952).","journal-title":"Le Press M\u00e9dicale"},{"key":"78446_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/10401230591002002","volume":"17","author":"F L\u00f3pez-Mu\u00f1oz","year":"2005","unstructured":"L\u00f3pez-Mu\u00f1oz, F. et al. History of the discovery and clinical introduction of chlorpromazine. Ann. Clin. Psychiatry 17, 113\u2013135 (2005).","journal-title":"Ann. Clin. Psychiatry"},{"key":"78446_CR30","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3109\/00048679309075791","volume":"27","author":"P Mitchell","year":"1993","unstructured":"Mitchell, P. Chlorpromazine turns forty. Aust. N. Z. J. Psychiatry 27, 370\u2013373 (1993).","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"78446_CR31","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1001\/jama.287.14.1860-JMS0410-6-1","volume":"287","author":"M Rosenbloom","year":"2002","unstructured":"Rosenbloom, M. Chlorpromazine and the psychopharmacologic revolution. J. Am. Med. Assoc. 287, 1860\u20131861 (2002).","journal-title":"J. Am. Med. Assoc."},{"key":"78446_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1021\/acschemneuro.8b00258","volume":"10","author":"D Boyd-Kimball","year":"2019","unstructured":"Boyd-Kimball, D. et al. Classics in chemical neuroscience: chlorpromazine. ACS Chem. Neurosci. 10, 79\u201388 (2019).","journal-title":"ACS Chem. Neurosci."},{"key":"78446_CR33","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/BF00449814","volume":"238","author":"HY Meltzer","year":"1989","unstructured":"Meltzer, H. Y., Bastani, B., Ramirez, L. & Matsubara, S. Clozapine: new research on efficacy and mechanism of action. Eur. Arch. Psychiatry Clin. Neurosci. 238, 332\u2013339 (1989).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"78446_CR34","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1021\/cn400121z","volume":"4","author":"CJ Wenthur","year":"2013","unstructured":"Wenthur, C. J. & Lindsley, C. W. Classics in chemical neuroscience: clozapine. ACS Chem. Neurosci. 4, 1018\u20131025 (2013).","journal-title":"ACS Chem. Neurosci."},{"key":"78446_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1021\/cn400189s","volume":"5","author":"P Seeman","year":"2014","unstructured":"Seeman, P. Clozapine, a fast-off-D2 antipsychotic. ACS Chem. Neurosci. 5, 24\u201329 (2014).","journal-title":"ACS Chem. Neurosci."},{"key":"78446_CR36","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1021\/acschemneuro.8b00159","volume":"9","author":"TC Chopko","year":"2018","unstructured":"Chopko, T. C. & Lindsley, C. W. Classics in chemical neuroscience: risperidone. ACS Chem. Neurosci. 9, 1520\u20131529 (2018).","journal-title":"ACS Chem. Neurosci."},{"key":"78446_CR37","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1021\/acschemneuro.7b00018","volume":"8","author":"MW Tyler","year":"2017","unstructured":"Tyler, M. W., Zaldivar-Diez, J. & Haggarty, S. J. Classics in chemical neuroscience: ketamine. ACS Chem. Neurosci. 8, 444\u2013453 (2017).","journal-title":"ACS Chem. Neurosci."},{"key":"78446_CR38","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/BF00431451","volume":"84","author":"TE Robinson","year":"1984","unstructured":"Robinson, T. E. Behavioral sensitization: characterization of enduring changes in rotational behavior produced by intermittent injections of amphetamine in male and female rats. Psychopharmacology 84, 466\u2013475 (1984).","journal-title":"Psychopharmacology"},{"key":"78446_CR39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0165-0173(86)90002-0","volume":"396","author":"TE Robinson","year":"1986","unstructured":"Robinson, T. E. & Becker, J. B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. 396, 157\u2013198 (1986).","journal-title":"Brain Res."},{"key":"78446_CR40","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/0014-2999(85)90395-4","volume":"109","author":"M Herrera-Marschitz","year":"1985","unstructured":"Herrera-Marschitz, M. Effect of the dopamine D-1 antagonist SCH 23390 on rotational behaviour induced by apomorphine and pergolide in 6-hydroxy-dopamine denervated rats. Eur. J. Pharmacol. 109, 349\u2013354 (1985).","journal-title":"Eur. J. Pharmacol."},{"key":"78446_CR41","first-page":"1","volume":"60","author":"A Carlsson","year":"1993","unstructured":"Carlsson, A. Thirty years of dopamine research. Adv. Neurol. 60, 1\u201310 (1993).","journal-title":"Adv. Neurol."},{"key":"78446_CR42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4088\/JCP.v64n0102","volume":"64","author":"SM Stahl","year":"2003","unstructured":"Stahl, S. M. & Shayegan, D. K. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J. Clin. Psychiatry 64, 6\u201312 (2003).","journal-title":"J. Clin. Psychiatry"},{"key":"78446_CR43","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.schres.2016.06.016","volume":"176","author":"AC Edwards","year":"2016","unstructured":"Edwards, A. C., Bacanu, S.-A., Bigdeli, T. B., Moscati, A. & Kendler, K. S. Evaluating the dopamine hypothesis of schizophrenia in a large-scale genome-wide association study. Schizophr. Res. 176, 136\u2013140 (2016).","journal-title":"Schizophr. Res."},{"key":"78446_CR44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00044-004-0017-7","volume":"13","author":"RB Mailman","year":"2004","unstructured":"Mailman, R. B. & Gay, E. A. Novel mechanisms of drug action: functional selectivity at D2 dopamine receptors. Med. Chem. Res. 13, 115\u2013126 (2004).","journal-title":"Med. Chem. Res."},{"key":"78446_CR45","doi-asserted-by":"publisher","first-page":"e0224691","DOI":"10.1371\/journal.pone.0224691","volume":"14","author":"A Mart\u00ednez","year":"2019","unstructured":"Mart\u00ednez, A., Ibarra, I. A. & Vargas, R. A quantum chemical approach representing a new perspective concerning agonist and antagonist drugs in the context of schizophrenia and Parkinson\u2019s disease. PLoS ONE 14, e0224691 (2019).","journal-title":"PLoS ONE"},{"key":"78446_CR46","first-page":"1","volume":"1","author":"A Mart\u00ednez","year":"2018","unstructured":"Mart\u00ednez, A. & Vargas, R. A component of the puzzle, when attempting to understand antipsychotics: a theoretical study of chemical reactivity indexes. J. Pharmacol. Pharm. Res. 1, 1\u20138 (2018).","journal-title":"J. Pharmacol. Pharm. Res."},{"key":"78446_CR47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5155\/eurjchem.11.1.84-90.1970","volume":"11","author":"A Mart\u00ednez","year":"2020","unstructured":"Mart\u00ednez, A. Dopamine antagonists for the treatment of drug addiction: PF-4363467 and related compounds. Eur. J. Chem. 11, 84\u201390 (2020).","journal-title":"Eur. J. Chem."},{"key":"78446_CR48","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn, M. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394, 939\u2013951 (2019).","journal-title":"Lancet"},{"key":"78446_CR49","doi-asserted-by":"publisher","first-page":"9037","DOI":"10.1021\/jp803218e","volume":"112","author":"A Mart\u00ednez","year":"2008","unstructured":"Mart\u00ednez, A., Rodr\u00edguez-Giron\u00e9s, M. A., Barbosa, A. & Costas, M. Donator acceptor map for carotenoids, melatonin and vitamins. J. Phys. Chem. A 112, 9037\u20139042 (2008).","journal-title":"J. Phys. Chem. A"},{"key":"78446_CR50","doi-asserted-by":"publisher","first-page":"D158","DOI":"10.1093\/nar\/gkw1099","volume":"45","author":"A Bateman","year":"2017","unstructured":"Bateman, A. et al. UniProt: The universal protein knowledgebase. Nucleic Acids Res. 45, D158\u2013D169 (2017).","journal-title":"Nucleic Acids Res."},{"key":"78446_CR51","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074\u2013D1082 (2018).","journal-title":"Nucleic Acids Res."},{"key":"78446_CR52","doi-asserted-by":"publisher","first-page":"D1091","DOI":"10.1093\/nar\/gkx1121","volume":"46","author":"SD Harding","year":"2018","unstructured":"Harding, S. D. et al. The IUPHAR\/BPS guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res. 46, D1091\u2013D1106 (2018).","journal-title":"Nucleic Acids Res."},{"key":"78446_CR53","unstructured":"NCATS. NCATS Creates Drug Development Data Portal. National Center for Advancing (2020)."},{"key":"78446_CR54","unstructured":"Frisch, M. J. et al. Gaussian 09, Revision A.08. (2009)."},{"key":"78446_CR55","doi-asserted-by":"publisher","first-page":"D1202","DOI":"10.1093\/nar\/gkv951","volume":"44","author":"S Kim","year":"2016","unstructured":"Kim, S. et al. PubChem substance and compound databases. Nucleic Acids Res. 44, D1202\u2013D1213 (2016).","journal-title":"Nucleic Acids Res."},{"key":"78446_CR56","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1063\/1.455064","volume":"89","author":"GA Petersson","year":"1988","unstructured":"Petersson, G. A. et al. A complete basis set model chemistry. I. The total energies of closed-shell atoms and hydrides of the first-row elements. J. Chem. Phys. 89, 2193\u20132218 (1988).","journal-title":"J. Chem. Phys."},{"key":"78446_CR57","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.1063\/1.460447","volume":"94","author":"GA Petersson","year":"1991","unstructured":"Petersson, G. A. & Al-Laham, M. A. A complete basis set model chemistry. II. Open-shell systems and the total energies of the first-row atoms. J. Chem. Phys. 94, 6081\u20136090 (1991).","journal-title":"J. Chem. Phys."},{"key":"78446_CR58","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.1063\/1.438980","volume":"72","author":"AD McLean","year":"1980","unstructured":"McLean, A. D. & Chandler, G. S. Contracted Gaussian basis sets for molecular calculations. I. Second row atoms, Z=11\u201318. J. Chem. Phys. 72, 5639\u20135648 (1980).","journal-title":"J. Chem. Phys."},{"key":"78446_CR59","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1063\/1.438955","volume":"72","author":"R Krishnan","year":"1980","unstructured":"Krishnan, R., Binkley, J. S., Seeger, R. & Pople, J. A. Self-consistent molecular orbital methods. XX. A basis set for correlated wave functions. J. Chem. Phys. 72, 650\u2013654 (1980).","journal-title":"J. Chem. Phys."},{"key":"78446_CR60","doi-asserted-by":"publisher","first-page":"6378","DOI":"10.1021\/jp810292n","volume":"113","author":"AV Marenich","year":"2009","unstructured":"Marenich, A. V., Cramer, C. J. & Truhlar, D. G. Universal solvation model based on solute electron density and on a continuum model of the solvent defined by the bulk dielectric constant and atomic surface tensions. J. Chem. Phys. B 113, 6378\u20136396 (2009).","journal-title":"J. Chem. Phys. B"},{"key":"78446_CR61","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1021\/jp065459f","volume":"111","author":"JL G\u00e1zquez","year":"2007","unstructured":"G\u00e1zquez, J. L., Cedillo, A. & Vela, A. Electrodonating and electroaccepting powers. J. Phys. Chem. A 111, 1966\u20131970 (2007).","journal-title":"J. Phys. Chem. A"},{"key":"78446_CR62","first-page":"3","volume":"52","author":"JL G\u00e1zquez","year":"2008","unstructured":"G\u00e1zquez, J. L. Perspectives on the density functional theory of chemical reactivity. J. Mex. Chem. Soc. 52, 3\u201310 (2008).","journal-title":"J. Mex. Chem. Soc."},{"key":"78446_CR63","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.1021\/jp8102436","volume":"113","author":"A Mart\u00ednez","year":"2009","unstructured":"Mart\u00ednez, A. Donator acceptor map of psittacofulvins and anthocyanins: are they good antioxidant substances?. J. Phys. Chem. B 113, 4915\u20134921 (2009).","journal-title":"J. Phys. Chem. B"},{"key":"78446_CR64","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.1021\/jp911846h","volume":"114","author":"JP Cer\u00f3n-Carrasco","year":"2010","unstructured":"Cer\u00f3n-Carrasco, J. P., Bastida, A., Requena, A., Zu\u00f1iga, J. & Miguel, B. A. Theoretical study of the reaction of \u03b2-carotene with the nitrogen dioxide radical in solution. J. Phys. Chem. B 114, 4366\u20134372 (2010).","journal-title":"J. Phys. Chem. B"},{"key":"78446_CR65","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s00894-014-2337-y","volume":"20","author":"RAD Alfaro","year":"2014","unstructured":"Alfaro, R. A. D., G\u00f3mez-Sandoval, Z. & Mammino, L. Evaluation of the antiradical activity of hyperjovinol-A utilizing donor-acceptor maps. J. Mol. Model. 20, 2337 (2014).","journal-title":"J. Mol. Model."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78446-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78446-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78446-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T19:48:58Z","timestamp":1670356138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78446-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,9]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["78446"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-78446-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,9]]},"assertion":[{"value":"27 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21581"}}